ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s clinical stage product candidates include: ORIC-533, an orally bioavailable small molecule inhibitor of CD73 which playing a role in resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-114, a brain penetrant, orally bioavailable, irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; and ORIC-944, an allosteric inhibitor of polycomb repressive complex 2 via the embryonic ectoderm development subunit. The ORIC average annual return since 2020 is shown above.
The Average Annual Return on the ORIC average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ORIC average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ORIC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|